Skip to main content

Table 3 Healthcare resource utilisation

From: Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries

  FRANCE GERMANY ITALY SPAIN SWEDEN UK
N 59 102 112 112 36 104
Medical consultations (HS + Private), n (%)
 GP 45 (76.3) 80 (78.4) 66 (58.9) 99 (88.4) 22 (61.1) 74 (71.2)
 Specialists 59 (100.0) 81 (79.4) 112 (100.0) 94 (83.9) 34 (94.4) 104 (100.0)
A) HS consultations
 Gastroenterologist, n (%) 59 (100.0) 51 (50.0) 112 (100.0) 67 (59.8) 23 (63.9) 104 (100.0)
 Mean visits (95% CI)a 2.2 (1.8, 2.6) 2.0 (1.5, 2.4) 4.0 (3.1, 5.0) 2.3 (1.9, 2.7) 1.7 (1.4, 2.0) 2.7 (2.3, 3.0)
 GP, n (%) 21 (35.6) 41 (40.2) 65 (58.0) 93 (83.0) 21 (58.3) 73 (70.2)
 Mean visits (95% CI)a 4.2 (2.4, 6.0) 4.3 (3.2, 5.5) 6.4 (4.0, 8.7) 3.8 (2.9, 4.7) 2.1 (1.4, 2.7) 6.2 (4.2, 8.3)
B) Private consultations
 Gastroenterologist, n (%) 19 (32.2) 46 (45.1) 33 (29.5) 47 (42.0) 12 (33.3) 4 (3.8)
 Mean visits (95% CI)a 1.9 (1.1, 2.7) 2.7 (1.7, 3.7) 2.1 (1.6, 2.6) 2.2 (1.6, 2.8) 2.3 (1.4, 3.1) 2.0 (0.0, 4.3)
 GP, n (%) 29 (49.2) 68 (66.7) 4 (3.6) 17 (15.2) 2 (5.6) 2 (1.9)
 Mean visits (95% CI)a 3.9 (2.7, 5.0) 4.2 (3.2, 5.2) 3.1 (0.0, 6.4) 3.6 (2.3, 4.9) 1.5 (0.0, 7.9) 5.0 (0.0, 55.8)
Hospitalisations or emergency room visits
 Any visit, n (%) 10 (16.9) 19 (18.6) 15 (13.4) 22 (19.6) 4 (11.1) 25 (24.0)
 Number of hospitalisations, mean (95% CI)b 1.5 (0.9, 2.0) 2.4 (1.3, 3.4) 1.8 (0.7, 2.9) 1.3 (1.0, 1.6) 2.5 (0.0, 5.3) 1.7 (1.2, 2.3)
 Median 1.0 1.0 1.0 1.0 2.1 1.0
 Number of days hospitalised, mean (95% CI)b 5.7 (0.0, 12.2) 19.7 (3.2, 36.2) 17.9 (0.0, 41.6) 1.5 (0.6, 2.4) 10.7 (0.0,28.3) 11.8 (2.5, 21.1)
 Median 3.1 9.0 6.0 1.5 12.0 6.0
Diagnostic tests
 Any test n (%) 34 (57.6) 68 (66.7) 83 (74.1) 65 (58.0) 22 (61.1) 54 (51.9)
 Number of tests, mean (95% CI)b 3.4 (2.4, 4.3) 4.0 (3.4, 4.6) 4.5 (3.9, 5.2) 4.1 (3.4, 4.7) 3.5 (2.5, 4.6) 3.6 (2.9, 4.4)
 Median 2.5 3.5 4.0 4.0 3.0 3.0
Pharmacological therapies, n (%)
 Prescription drug 31 (52.5) 73 (71.6) 54 (48.2) 95 (84.8) 33 (91.7) 97 (93.3)
 Prescription drug for IBS-C 30 (50.8) 56 (54.9) 46 (41.1) 89 (79.5) 28 (77.8) 94 (90.4)
 Non-prescription drug for IBS-C 36 (61.0) 71 (69.6) 92 (82.1) 63 (56.3) 25 (69.4) 66 (63.5)
 Complementary therapies, n (%) 18 (30.5) 28 (27.5) 41 (36.6) 33 (29.5) 16 (44.4) 37 (35.6)
Absenteeism and work impairment questionnaire for employed patients (over one year)
 Any sick leave taken, n (%) 12 (38.7) 19 (33.9) 15 (21.4) 14 (23.7) 12 (44.4) 33 (50.8)
 Number of times on sick leave, mean (95% CI)c 3.3 (1.0, 5.6) 4.5 (3.0, 6.0) 6.9 (3.5, 10.2) 6.3 (1.9, 10.6) 5.7 (0.8, 10.6) 5.2 (3.8, 6.6)
 Number of days on sick leave, mean (95% CI)c 64.1 (17.0, 111.2) 29.5 (10.5, 48.5) 11.6 (4.1, 19.2) 52.4 (0.0, 114.4) 51.3 (0.0, 113.6) 25.9 (12.7, 39.1)
 Any work impairment while working, n (%) 16 (51.6) 37 (66.1) 18 (25.7) 31 (52.5) 19 (70.4) 53 (81.5)
 Number of hours of work impairment, mean (95% CI)c 69.1 (22.0, 116.1) 140.4 (88.8, 192.0) 83.2 (18.4, 148.0) 54.8 (34.0, 75.7) 280.3 (146.5, 414.1) 161.9 (103.6, 220.2)
  1. aNumber of visits (calculated in patients with at least 1 visit)
  2. bCalculated in patients with at least one hospitalisation/diagnostic test
  3. cIn patients with at least one sick leave.
  4. 95% CI 95% Confidence Interval, GP General practitioner/family doctor, HS Healthcare system